Loading stock data…
$8.75-0.05 (-0.57%)
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
Alpha Cognition Inc. Common Stock in the Healthcare sector is trading at $8.75 with a market capitalization of $198M. Wall Street consensus targets $18.00 (5 analysts), implying a +105.7% move over the next 12 months. The stock is currently 14% below its 52-week high of $10.14, remaining 24.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.09M↑ | $3.53M↑ | $2.79M↓ | $2.84M↑ | $1.66M |
| Gross Profit | $5.70M↑ | $3.26M↑ | $2.54M↑ | $2.21M↑ | $1.45M |
| Operating Income | -$7.76M↑ | -$8.10M↓ | -$7.93M↓ | -$5.30M↑ | -$8.45M |
| Net Income | -$8.79M↓ | -$6.48M↑ | -$6.86M↓ | -$1.32M↑ | -$13.20M |
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tab...